GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (FRA:RYH0) » Definitions » 3-Year Sharpe Ratio

Sareum Holdings (FRA:RYH0) 3-Year Sharpe Ratio : -0.28 (As of Jun. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Sareum Holdings 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-06-28), Sareum Holdings's 3-Year Sharpe Ratio is -0.28.


Competitive Comparison of Sareum Holdings's 3-Year Sharpe Ratio

For the Biotechnology subindustry, Sareum Holdings's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sareum Holdings's 3-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sareum Holdings's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Sareum Holdings's 3-Year Sharpe Ratio falls into.


;
;

Sareum Holdings 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


Sareum Holdings  (FRA:RYH0) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Sareum Holdings 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Sareum Holdings's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sareum Holdings Business Description

Traded in Other Exchanges
Address
Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.

Sareum Holdings Headlines

No Headlines